摘要
目的·探讨血清S100B蛋白水平与双相障碍抑郁发作及其预后的相关性。方法·根据美国精神病协会《精神障碍诊断与统计手册》第4版(DSM-Ⅳ)诊断标准,入组双相障碍抑郁发作患者80例(病例组)以及健康对照者42名(对照组)。病例组患者采用随机数字表法进入碳酸锂联合喹硫平治疗组(喹硫平组)及碳酸锂合并改良无抽搐电休克治疗组(MECT组);治疗前及治疗4周末分别测定2组血清S100B水平并评定汉密尔顿抑郁量表(HAMD)。结果·经过4周随访,喹硫平组共完成36例,MECT组完成31例。病例组治疗前血清S100B水平显著高于对照组(P=0.000);治疗后,喹硫平组与MECT组患者血清S100B水平均较治疗前显著下降,HAMD评分均较治疗前显著降低(P=0.000);Pearson相关分析显示病例组治疗前后血清S100B变化水平与HAMD评分变化值呈正相关(r=0.33,P=0.013)。结论·S100B可能与双相障碍抑郁发作以及预后有关。
Objective · To explore the correlation of serum S100B protein with depressive episode of bipolar disorder （BD） and its prognosis. Methods · Based on BD criteria of Diagnostic and Statistical Manual of Mental Disorders 4th edition （DSM-Ⅳ ）, 80 patients with depressive episode of BD （case group） and 42 healthy controls （control group） were enrolled. Patients were randomly assigned into quetiapine group who were treated with lithium and quetiapine and modified electroconvulsive therapy （MECT） group who received lithium and MECT. The serum S100B level and Hamilton Rating Scale for Depression （HAMD） were assayed before and after 4-week treatment. Results · The serum S100B levels before treatment in patients with depressive episode of BD were significantly higher than those in healthy controls （P=0.000）. The levels of S100B in both drug and MECT groups decreased after 4-week treatment. The HAMD score after treatment significantly decreased than that before treatment （P=0.000）. Pearson correlation analysis showed that the change of S100B level was positively correlated with the change of HAMD score before and after treatment in case group （r=0.33, P=0.013）. Conclusion · S100B may be associated with depressive episode of BD and its prognosis.
出处
《上海交通大学学报（医学版）》
CSCD
北大核心
2017年第6期769-773,共5页
Journal of Shanghai Jiao tong University:Medical Science
基金
国家自然科学基金(81471358)
金华市科学技术局重点项目(2015-3-022)
上海市科学技术委员会项目(14411969000)
上海市教育委员会高峰高原学科建设计划(20152530)
上海市卫生与计划生育委员会科研项目(201540029)~~
关键词
双相障碍
抑郁发作
S100B
无抽搐电休克治疗
bipolar disorder
depressive episode
S 100B
modified electroconvulsive therapy
